Login to Your Account



Targacept, AZT Depression Drug Candidate Enters Home Stretch

By Catherine Hollingsworth


Thursday, June 24, 2010
Targacept Inc. and AstraZeneca have enrolled the first patient in a Phase III program for depression drug candidate TC-5214, which showed positive results in Phase II testing as an add-on therapy for patients who did not respond well to prior treatment with another antidepressant, citalopram. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription